BriaCell Completes 15-for-1 Share Consolidation
BriaCell Therapeutics Corp., a leading clinical-stage biotechnology company, has recently announced a noteworthy milestone in its journey towards transforming cancer care. The company has executed a share consolidation on a 15-for-1 basis, significantly reducing their number of common shares. This strategic move is vital as BriaCell aims to maintain compliance with The Nasdaq Capital Market’s listing standards.
Understanding the Share Consolidation
The consolidation, which became effective on January 24, 2025, adjusted the company’s issued and outstanding common shares from over 44 million to approximately 2.9 million. This reduction is designed to strengthen the company's ability to attract investors and ensure compliance on major stock exchanges like Nasdaq and the Toronto Stock Exchange (TSX).
Transaction Details
The new shares under this consolidation are set to begin trading after the market opens on January 29, 2025. Post-consolidation, the shares will be listed under the same ticker symbols, “BCT” for TSX and “BCTX” for Nasdaq. This strategic decision was made after careful consideration of market conditions and future growth prospects.
Handling Fractional Shares
For shareholders, it’s important to note that fractional common shares have been managed during this transition. Shares that were less than half a share have been canceled, while those equal to or exceeding half a share have been converted to full common shares. This adjustment assures that all outstanding convertible securities and their terms have also been proportionately modified.
Next Steps for Shareholders
BriaCell is taking proactive measures to inform shareholders about the consolidation process. For those holding shares in book form, the transition will occur automatically, while shareholders with physical certificates need to submit a completed Letter of Transmittal to convert their holdings to the new share structure. The company’s transfer agent has already started distributing these forms to facilitate this process.
Future Outlook for BriaCell
BriaCell remains dedicated to its mission of developing innovative immunotherapies. As a clinical-stage company, BriaCell is committed to enhancing cancer treatment using advanced technologies and therapies. The share consolidation is just one of several strategic initiatives BriaCell is undertaking to optimize its market presence and foster growth.
About BriaCell Therapeutics Corp.
BriaCell is at the forefront of biotechnology with a focus on creating groundbreaking immunotherapy solutions for cancer patients. By continuously advancing its research and clinical trials, BriaCell aims to revolutionize cancer care and improve patient outcomes.
Frequently Asked Questions
What is a share consolidation?
A share consolidation is a process where a company reduces the total number of its outstanding shares to increase the per-share price. In this case, BriaCell’s shares were consolidated at a 15-for-1 ratio.
Why did BriaCell conduct a share consolidation?
The consolidation helps BriaCell comply with stock exchange listing standards while making its shares more attractive to investors.
What happens to fractional shares after consolidation?
Fractional shares less than half a share are canceled, while those of at least half a share are converted into full shares.
When will the new shares start trading?
The post-consolidation shares are expected to commence trading on January 29, 2025.
How can shareholders obtain information about their shares?
Shareholders can contact the company’s transfer agent or refer to their intermediaries for assistance regarding their shares and the consolidation process.
